Clinical Trial

Anti-protozoal Effect of Steroid Hormone 20-hydroxyecdysone

Active, Not Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
20-hydroxyecdysone is an ecdysteroid hormone found in invertebrates and plants. 20-hydroxyecdysone exhibits a broad range of biological properties in various in vitro and in vivo models, including anabolic, antioxidant, anti-inflammatory, immunomodulatory, anti-obesity and antidiabetic activities, in addition to acting as neuroprotective and hepatoprotective agent. Ecdysteroids are widely used by athletes as dietary supplements to increase strength and muscle mass during resistance training, to reduce fatigue and to ease recovery. Mhashilkar AS et al. (2016) were revealed anti-parasitic activity of 20-hydroxyecdysone against the human filarial parasites. According to recent searches in academic databases and medical search engines (Google, www.google.com; PubMed, www.ncbi.nlm.nih.gov/pubmed; and Medline, www.medline.com), no studies have been conducted to assess the anti-protozoal activity of 20-hydroxyecdysone. The aim of the study is to assess anti-protozoal activity of 20-hydroxyecdysone in water sports athletes with giardiasis.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2021-03-30; most recent amendment 2025-04-01.
Trial Details
NCT Number NCT04827537
Lead Sponsor Research Institute of Epidemiology, Microbiology and Infectious Diseases, Uzbekistan
Conditions Giardia Lamblia Infection
Enrollment 200 participants
Start Date 2021-01-01
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-04-04